Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma.
Renal cell carcinoma (RCC)
S100A1
caveolin-1
chromophobe
cytokeratin 7
immunohistochemistry
oncocytoma
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
27
6
2019
Statut:
ppublish
Résumé
Differentiation of chromophobe renal cell carcinoma (chRCC) from benign renal oncocytoma (RO) can be challenging especially when there are overlapping histological and morphological features. In this study we have investigated immunohistochemical biomarkers (cytokeratin 7/CK7, Caveolin-1/Cav-1 and S100 calcium-binding protein A1/S100A1) to aid in this difficult differentiation and attempted to validate their use in human renal tumour tissue to assess their discriminatory ability, particularly for chRCC and RO, in an Australian cohort of patients. Retrospective study was carried out of archived formalin-fixed paraffin-embedded renal tumours from tumour nephrectomy specimens of 75 patients: 30 chRCC, 15 RO and 30 clear cell RCC (ccRCC). Sections were cut and immunostained with specific polyclonal antibodies of CK7, Cav-1 and S100A1. Morphometry was used to determine expression patterns of the biomarkers using Aperio ImageScope. Results were assessed with student From this cohort, male-to-female ratio was 1.9:1. Median age was 64 (45-88 years) and median tumour size was 3.8 cm (range, 1.2-18 cm). There were 47 (62.7%) T1, 7 T2, 20 T3 and one T4 stage of RCC; with 2 patients presenting with M1 stage. There was significantly higher CK7 expression in chRCC compared to RO (P=0.03), and chRCC also had a different staining pattern and higher expression of Cav-1 compared to RO. There was higher expression of S100A1 in RO compared to chRCC. Immunohistochemical staining and standard morphometry of CK7, Cav-1 and S100A1 can aid in the differentiation of chRCC and RO. This may guide clinicians in management of patients when faced with difficult diagnostic histological distinction between the two tumour subtypes.
Sections du résumé
BACKGROUND
BACKGROUND
Differentiation of chromophobe renal cell carcinoma (chRCC) from benign renal oncocytoma (RO) can be challenging especially when there are overlapping histological and morphological features. In this study we have investigated immunohistochemical biomarkers (cytokeratin 7/CK7, Caveolin-1/Cav-1 and S100 calcium-binding protein A1/S100A1) to aid in this difficult differentiation and attempted to validate their use in human renal tumour tissue to assess their discriminatory ability, particularly for chRCC and RO, in an Australian cohort of patients.
METHODS
METHODS
Retrospective study was carried out of archived formalin-fixed paraffin-embedded renal tumours from tumour nephrectomy specimens of 75 patients: 30 chRCC, 15 RO and 30 clear cell RCC (ccRCC). Sections were cut and immunostained with specific polyclonal antibodies of CK7, Cav-1 and S100A1. Morphometry was used to determine expression patterns of the biomarkers using Aperio ImageScope. Results were assessed with student
RESULTS
RESULTS
From this cohort, male-to-female ratio was 1.9:1. Median age was 64 (45-88 years) and median tumour size was 3.8 cm (range, 1.2-18 cm). There were 47 (62.7%) T1, 7 T2, 20 T3 and one T4 stage of RCC; with 2 patients presenting with M1 stage. There was significantly higher CK7 expression in chRCC compared to RO (P=0.03), and chRCC also had a different staining pattern and higher expression of Cav-1 compared to RO. There was higher expression of S100A1 in RO compared to chRCC.
CONCLUSIONS
CONCLUSIONS
Immunohistochemical staining and standard morphometry of CK7, Cav-1 and S100A1 can aid in the differentiation of chRCC and RO. This may guide clinicians in management of patients when faced with difficult diagnostic histological distinction between the two tumour subtypes.
Identifiants
pubmed: 31236330
doi: 10.21037/tau.2018.11.02
pii: tau-08-S2-S123
pmc: PMC6559932
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S123-S137Déclaration de conflit d'intérêts
Conflicts of Interest: Author’s Note: This manuscript was adapted from material included in Dr. Keng Lim Ng’s PhD Thesis.
Références
Mod Pathol. 1999 Mar;12(3):310-7
pubmed: 10102617
Am J Surg Pathol. 1999 May;23(5):530-5
pubmed: 10328084
J Biol Chem. 1999 Jul 30;274(31):21491-4
pubmed: 10419448
Eur Urol. 2000 Apr;37(4):484-7
pubmed: 10765081
Cancer Lett. 2002 Jan 10;175(1):71-7
pubmed: 11734338
Histopathology. 2002 Jun;40(6):563-7
pubmed: 12047768
Mod Pathol. 2002 Jul;15(7):712-7
pubmed: 12118108
Urol Oncol. 2003 May-Jun;21(3):191-6
pubmed: 12810205
Urology. 2003 Nov;62(5):827-30
pubmed: 14624902
Histol Histopathol. 2004 Jan;19(1):23-8
pubmed: 14702167
J Urol. 2004 Aug;172(2):718-22
pubmed: 15247769
Physiol Rev. 2004 Oct;84(4):1341-79
pubmed: 15383654
Hum Pathol. 2005 Jan;36(1):22-8
pubmed: 15712178
Eur J Surg Oncol. 2005 Apr;31(3):299-303
pubmed: 15780567
Am J Surg Pathol. 2005 Jun;29(6):747-54
pubmed: 15897741
Virchows Arch. 2005 Dec;447(6):938-46
pubmed: 16133362
Am J Clin Pathol. 2006 Mar;125(3):392-8
pubmed: 16613342
Anal Quant Cytol Histol. 2006 Aug;28(4):228-36
pubmed: 16927643
Clin Cancer Res. 2006 Dec 15;12(24):7215-20
pubmed: 17189392
Am J Clin Pathol. 2007 Feb;127(2):225-9
pubmed: 17210525
Histopathology. 2007 Apr;50(5):642-7
pubmed: 17394501
Mod Pathol. 2007 Jul;20(7):722-8
pubmed: 17483815
Cancer. 2007 Aug 15;110(4):776-82
pubmed: 17594718
Arch Pathol Lab Med. 2007 Aug;131(8):1290-7
pubmed: 17683191
Int J Cancer. 2008 Aug 1;123(3):569-76
pubmed: 18478571
Indian J Pathol Microbiol. 2008 Apr-Jun;51(2):167-71
pubmed: 18603673
Histopathology. 2009 Apr;54(5):633-5
pubmed: 19302533
Mol Cancer Res. 2009 Nov;7(11):1781-91
pubmed: 19903767
Histopathology. 2011 Jan;58(2):169-79
pubmed: 21323945
Korean J Urol. 2011 Feb;52(2):96-103
pubmed: 21379425
Med Mol Morphol. 2011 Jun;44(2):111-5
pubmed: 21717314
J Urol. 2011 Oct;186(4):1218-22
pubmed: 21849182
Appl Immunohistochem Mol Morphol. 2012 Oct;20(5):454-61
pubmed: 22417859
Med Mol Morphol. 2012 Jun;45(2):98-104
pubmed: 22718295
Ann Diagn Pathol. 2013 Feb;17(1):58-62
pubmed: 22898056
J Transl Med. 2013 Oct 11;11:255
pubmed: 24119769
Eur Urol. 2014 Nov;66(5):795-8
pubmed: 24890805
Can Urol Assoc J. 2014 Jul;8(7-8):247-52
pubmed: 25210548
Cancer Cytopathol. 2015 May;123(5):298-305
pubmed: 25739652
Int J Clin Exp Med. 2015 Nov 15;8(11):20760-8
pubmed: 26884999
J Clin Pathol. 2016 Aug;69(8):661-71
pubmed: 26951082
Trends Biochem Sci. 1996 Apr;21(4):134-40
pubmed: 8701470
Cancer. 1997 Sep 1;80(5):994-6
pubmed: 9307206
Arch Pathol Lab Med. 1997 Oct;121(10):1081-6
pubmed: 9341588
J Histochem Cytochem. 1998 Feb;46(2):205-14
pubmed: 9446827
J Biol Chem. 1998 Mar 6;273(10):5419-22
pubmed: 9488658
Annu Rev Biochem. 1998;67:199-225
pubmed: 9759488